Carboplatin

Catalog No.S1215 Synonyms: JM-8, CBDCA, NSC 241240

Carboplatin Chemical Structure

Molecular Weight(MW): 371.25

Carboplatin is a DNA synthesis inhibitor by binding to DNA and interfering with the cell's repair mechanism in A2780, SKOV-3, IGROV-1, and HX62 cells.

Size Price Stock Quantity  
USD 77 In stock
USD 107 In stock
USD 167 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

4 Customer Reviews

  • (A) The BRCA1-mutated TNBC cell lines MDA-MB-436 and HCC1937 were treated with CBP (10 μM) plus GEM (100 nM) combined with or without olaparib (10 μM) for the indicated times, and then, the cell viability was determined with an MTT assay. The results show data from six independent experiments expressed as the mean ± SD. p < 0.05.

    Sci Rep, 2017, 7:42319. Carboplatin purchased from Selleck.

    Detection of apoptotic responses was found to increase in epimorphin-treated  A1847 with increasing concentrations of carboplatin compared to those of the untreated controls. Data were normalized to the controls and are represented as means ± S.D. [*p<0.05 compared with control]. Images of apoptotic cells were captured at 10X magnification, with at least 3 images per well, using an upright phase-contrast microscope (T3.15A; Fisher Scientific).

    PLoS One 2012 8, e72637. Carboplatin purchased from Selleck.

  • A. MCF10A-Ras overexpressing a vector control or the gene of interest (GeneX), or MCF7 expressing a scramble or a siRNA for the geneX were treated with DMSO or with Carboplatin for 24h. Resistant colonies were allowed to grow for 2 weeks, and are then stained with Crystal Violet. B. Quantification of the results.

     

     

    Dr. Helen Sadik of Johns Hopkins University. Carboplatin purchased from Selleck.

    Cells were seeded in 96 well paltes, and then treated with the indicated concentration of Carboplatin for 48h. Cell survival was measured by a standarad MTT assay.

     

     

    Dr. Helen Sadik of Johns Hopkins University. Carboplatin purchased from Selleck.

Purity & Quality Control

Choose Selective DNA/RNA Synthesis Inhibitors

Biological Activity

Description Carboplatin is a DNA synthesis inhibitor by binding to DNA and interfering with the cell's repair mechanism in A2780, SKOV-3, IGROV-1, and HX62 cells.
Features A DNA synthesis inhibitor.
Targets
DNA synthesis [1]
(A2780, SKOV-3, IGROV-1, HX62 cells)
In vitro

Carboplatin exhibits an inhibitory effect on cell proliferation in a human ovarian cancer cell line panel, including A2780, SKOV3, and IGROV-1 cells with IC50 of 6.1 μM, 12.4 μM and 2.2 μM, respectively. [1] Carboplatin also show the anti-proliferative activities in lung carcinoid cell line, such as UMC-11, H727, and H835 cells with IC50 of 36.4 μM, 3.4 μM and 35.8 μM, respectively. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Tca8113/ut  MlzvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3y3[FIuOjYkgJpOwG0> M3OwOFczKGh? NV\5PFNkcW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= MoTYNlYyOzdzMEW=
Tca8113/CBP  NXXWUHF5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHW4PJEzNTJ34pEJ{txO Mlj0O|IhcA>? NH70TZdqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 MofaNlYyOzdzMEW=
Tca8113/PYM  M{f3O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4nZXVIuOjYkgJpOwG0> Mo\ZO|IhcA>? M4LLOIlvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? NW\6e497OjZzM{exNFU>
SKOV3 M{e2fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVW2NEBu\y:vbB?= NIm4Z5IyNTViZB?= M1:0dIlvcGmkaYTzJINmdGxidnnhZoltcXS7IITpcYUh\GWyZX7k[Y51dHl? MXiyOlE{PzB2Mx?=
SKOV3 NIT0R5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXrZ3gxNTRizsznM41t MUmyOE81QC95MjDo NGrHT45qdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGGwZDD0bY1mKGSncHXu[IVvfGy7 NYL3OFJuOjZzMkWyO|M>
SKOV3 NHSyV|VCeG:ydH;zbZMhSXO|YYm= NGH5SpAzKM7:Zz;tcC=> NYXSeIpiPDhiaB?= MUXpcoR2[2W|IHHwc5B1d3Orcx?= MVuyOlEzPTJ5Mx?=
OSA M2Lr[mNtd26xZ3XubYMhSXO|YYm= NUD0bVhPOi53L{Wg{txO NFrjWIFz\XO3bITzJIlvKGyxd3XyJINwdG:weTDmc5Ju[XSrb36gZZMh[2:vcHHy[YQhfG9iZXn0bIVzKEKPSUGgd4lTVkFidILlZZRu\W62 NGjS[mIzPjFzME[yNC=>
A549 NVK3blJtTnWldHnvckBCe3OjeR?= MU[wM|I2NzVyIN88US=> MmS5NlQhcA>? NIK3Uo1ld3ewcnXneYxifGW|IH3pVk0zODViZYjwdoV{e2mxbtMg NX7HOGFnOjV7MUezNVc>
H1975 NIfuZ5hHfWO2aX;uJGF{e2G7 MnLlNE8zPS93MDFOwG0> M3LKVlI1KGh? NUXMUld{\G:5boLl[5Vt[XSnczDtbXIuOjB3IHX4dJJme3Orb39CpC=> NYP6Z3hOOjV7MUezNVc>
A549 NHfYdnRHfWO2aX;uJGF{e2G7 MUOwM|I2NzVyIN88US=> NXvhfYM1OjRiaB?= NYfCPXBGfXC{ZXf1cIF1\XNibXnSMVIyQCCneIDy[ZN{cW:w M1fNVFI2QTF5M{G3
H1975 NULn[5oyTnWldHnvckBCe3OjeR?= NYrCUItrOC9{NT:1NEDPxE1? MmnUNlQhcA>? NFe1[Wt2eHKnZ4XsZZRmeyCvaWKtNlE5KGW6cILld5Nqd25? MVmyOVkyPzNzNx?=
A549 MkTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUTORlFOOjVizszN M13FW|I1KGh? MlftbY5pcWKrdIOgZ4VtdCCpcn;3eIg> NWHQbY95OjV7MUezNVc>
H1975 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3rBWVI2KM7:TR?= NGmzemczPCCq NXPjO21JcW6qaXLpeJMh[2WubDDndo94fGh? NHvBXm4zPTlzN{OxOy=>
MDA-MB-231 Mn7DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX22XYdYOC1{MkCg{txoN22u MlnRO|IhcA>? NVHSZoZJUUN3MNMgQUA5PiEQvF2= NWTFZ2poOjV6M{e2PVE>
T47D MnTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWG3Tpk2OC1{MkCg{txoN22u NHXmNJA4OiCq Mm\MTWM2OMLiPTC0PE46KM7:TR?= M1uw[lI2QDN5Nkmx
LCTCC MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;IdHd2UUN3ME2zMljjiIoEtV2= M3Lqc|I2Pzd|MU[3
MCTCC NFLSbnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjxTWM2OD1{LklihKnDvU1? NYjqU5ByOjV5N{OxOlc>
MegTCC M4XNWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHTG[IhKSzVyPUSuNgKBkcL3TR?= NIOxWpozPTd5M{G2Oy=>
MonoTCC MnnFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnrnTWM2OD13LkdihKnDvU1? M4jYcFI2Pzd|MU[3
MCF7 MlzIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\nT|IxKM7:TR?= NUTiZm5HPzJiaB?= MXnpcoR2[2W|IHPlcIwh\GWjdHigc4YhUFBzzsKt[IVxdGW2ZXSgUWNHPyClZXzsdy=> MYGyOVc3QTB{NR?=
A-549  MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVL4bZZEOC53IN88US=> MoLINlQhcA>? M2L5b2ROW00EoB?= MWnpcohq[mm2czDj[YxtKGe{b4f0bEB{cWewaX\pZ4FvfGy7 Ml7pNlU4PTV4OUC=
A-549  NYjR[JBbSXCxcITvd4l{KEG|c3H5 NU\3eHdVOC53IN88US=> MkHIOFghcA>? M2S5[WROW00EoB?= M3O1dJNpd3e|IHXhdox6KGGyb4D0c5NqeyCoZXH0eZJmeyCrbnPseYRqdmdiYnzlZoJqdmdiYX7kJINpem:vYYTpckBkd26mZX7zZZRqd25? NEL0RXkzPTd3NU[5NC=>
A-549  MoTJSpVkfGmxbjDBd5NigQ>? MV2wMlUh|ryP MVu0PEBp M{\yT2ROW00EoB?= MXTzbI94eyCjYnXydoFvfCCvaXPyc5R2[nWuZTDkbZNzfXC2aX;u NUjI[5d[OjV5NUW2PVA>
A-549  MWnGeYN1cW:wIFHzd4F6 NWHyOZR3OC53IN88US=> MXW0PEBp MmPiSG1UV8Li Mk\NbY5pcWKrdIOgc4Yh[2WubDDtbYdz[XSrb39CpC=> MWGyOVc2PTZ7MB?=
RMG-1 NH65d4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTJ6LkigxtEhOy54IH3nM2w> MlfXNlU4OjZ7MUO=
FN-RMG-1 M2[0bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rwU2lEPTB;NECuOUDDuSB2LkKgcYcwVApizszN M4C0TVI2PzJ4OUGz
RMG-1-hFUT MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XjUmlEPTB;NUiuNUDDuSB{LkSgcYcwVA>? M1;UWVI2PzJ4OUGz
FN-RMG-1-hFUT NIDUcolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTFzOD64JOKyKDF|LkigcYcwVA>? MWWyOVczPjlzMx?=
CHP-134  NGXCTplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHQXYlyOSEQvF2= M1v5S2ROW00EoB?= NWjZPItOcW6qaXLpeJMhe2mpbnnmbYNidnRiY3XscEBoem:5dHigZ49u[mmwZXSge4l1cCCJU1uyPFMxOzdz MWSyOVY2QDR4Mx?=
IMR-32 MmTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4X6S|Eh|ryP MYnEUXNQyqB? MkLibY5pcWKrdIOgd4lodmmoaXPhcpQh[2WubDDndo94fGhiY3;tZolv\WRid3n0bEBIW0t{OEOwN|cy Mk[1NlU3PTh2NkO=
CHP-134  NVjiZplWTnWldHnvckBCe3OjeR?= NGPYeo8yOCEQvF5CpC=> MoPCSG1UV8Li NXjsV|UycW6mdXPld{BieG:ydH;zbZMhe2mpbnnmbYNidnSueTDjc41jcW6nZDD3bZRpKEeVS{K4N|A{PzF? M2D5ZVI2PjV6NE[z
IMR-32 NGq4flVHfWO2aX;uJGF{e2G7 NFO2NFkyOCEQvF5CpC=> NV7J[VIzTE2VT9Mg NG\2PIdqdmS3Y3XzJIFxd3C2b4Ppd{B{cWewaX\pZ4FvfGy7IHPvcYJqdmWmIIfpeIghT1ONMkizNFM4OQ>? Mkj4NlU3PTh2NkO=
A549 NUHufIlIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\pNE4zNTRyMECg{txO MXq3NkBp MWHJR|UxRTF{NjFCtUA2NjBizszN NXnJUWk{OjV4MkWyOFM>
A549/CDDP NU\QN3RzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWTFOXppOC5{LUSwNFAh|ryP MonoO|IhcA>? MkjJTWM2OD1{NEFCpOKyyqB2NT63JO69VQ>? NHzXNYszPTZ{NUK0Ny=>
H460  NIXVO5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;DeW16OjRiaB?= MYPEUXNQ MWfJR|UxRTdwOTFOwG0> NFvUSFIzPTV7OUm5OS=>
H460  NWrTcVJXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jjVlcvQSEQvF2= NF\sOW4zPCCq MorxSG1UVw>? M17LepNpd3e|IHGgdoFlcW:|ZX7zbZRqgmmwZzDl[oZm[3RidH:gXE1z[Xm| Mmj0NlU2QTl7OUW=
NRK-52E NXzve2tvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPwR4k4OsLiaNMg Mmr1TWM2OD1zMECgxtEhOTJwOTFOwG0> NEC1RpkzPTV4NU[wNy=>
RGE NVS0[mp6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlX3O|LDqGkEoB?= MmS3TWM2OD1{MjFCtUA4NjRizszN M2D6[VI2PTZ3NkCz
NRK-52E M4PFW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDZNpdiPzMEoHlCpC=> Mmf3TWM5OD1zN{mgxtEhQS53IN88US=> M1fLOVI2PTZ3NkCz
RGE MoHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXG3NuKhcMLi Mlf3TWM5OD14MzFCtUA4NjRizszN NV7nd3lIOjV3NkW2NFM>
SK-OV-3 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13Ud|czKGh? NYe3eWJNUUN3ME2xNFQvQCEQvF2= NEDRXWwzPTV{MEGzNi=>
ES-2 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXLO|IhcA>? M4\OUmlEPTB;MUSuOkDPxE1? Mn72NlU2OjBzM{K=
OVCAR-8 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXS3NkBp NXrtSJpwUUN3ME25Ok4xKM7:TR?= MVGyOVUzODF|Mh?=
3AO MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnwVWU4OiCq M4L6SGlEPTB;NkOuOEDPxE1? M37ubFI2PTJyMUOy
A2780 NGW1T2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWS3NkBp MVjJR|UxRTF2NT63JO69VQ>? MYeyOVUzODF|Mh?=
SW626 M2jzOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXu3NkBp M3H0SGlEPTB;OUeuNEDPxE1? NGXXbo8zPTV{MEGzNi=>
OVCAR-3 NHHOOIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWi3NkBp MWXJR|UxRTN{Lk[g{txO NXeyfnIyOjV3MkCxN|I>
A549 M{\ob2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjxRZRKSzVyPUG1NU42PiEEsTC1N{4xPiEQvF2= NVvJdm82OjV{N{e0OlE>
4T1 M1PM[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DjNmlEPTB;OESuOlIhyrFiM{CuNFUh|ryPCjFOwG0> MVyyOVI4PzR4MR?=
BALB/3T3 M1jQbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDGTWM2OD1zND6zNEDDuSB4Lk[4JO69VQ>? M33WXlI2Ojd5NE[x
B16 NXjYPGYxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnfRTWM2OD14ND6zNEDDuSB4LkixJO69VQ>? M2L0S|I2Ojd5NE[x
DU 145 NFK0UFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYD0c2RvUUN3ME2zOU4xPCEEsTCxO{42PCEQvF2= NVnPTnh7OjV{N{e0OlE>
FaDu NWrlXYdZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTR3LkO5JOKyKDFzLkWwJO69VQ>? MU[yOVI4PzR4MR?=
HCV-29T Mm\WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTR6LkW3JOKyKDJ{LkS5JO69VQ>? NYHFWnJCOjV{N{e0OlE>
HL-60 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHobGpKSzVyPUGxMlExKMLzIESuOFch|ryP MYiyOVI4PzR4MR?=
HT-29 MmSwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zjdWlEPTB;OEmuNVYhyrFiMUiuPFYh|ryP NUHWS|dxOjV{N{e0OlE>
H146 MmG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTR7LkdCtVE{NjFizszN M{jnVVI2OTJ2Mkiy
H187 MoXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mly0TWM2OD1zMj63xtEzNjdizszN NX\JVWpEOjVzMkSyPFI>
H128 M{fmUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{D3emlEPTB;MUC2MlTDuTlwNjFOwG0> NI\3SXAzPTF{NEK4Ni=>
H69 NFL2SJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PNN2lEPTB;N{[uPeKyOjdwODFOwG0> NV;zVXA6OjVzMkSyPFI>
H209 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\xZ2lEPTB;MkW4MlHDuTl7Lkig{txO NWLFfplUOjVzMkSyPFI>
DMS153 MkG5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlX3TWM2OD13Nz64xtE6NjJizszN M1\PPFI2OTJ2Mkiy
H526 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3nqcmlEPTB;Nz6yxtEyNjdizszN MXyyOVEzPDJ6Mh?=
DMS114 M{fsd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTh3LklCtVEzNjhizszN NEnheWczPTF{NEK4Ni=>
DMS53 MoL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\iTWM2OD1zNE[uNuKyOzZwNDFOwG0> M2D0RVI2OTJ2Mkiy
HeLa NULVWHRnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NELR[ZM2NThyIN88US=> NEXZU4JqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 MmPxNlUyODl|NkC=
MCF-7 M2PYdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVrnR|BbPS16MDFOwG0> NVfPSFc{cW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>? NV\HfG5GOjVzMEmzOlA>
MDA-MB-231 MkLWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;ReJkxPS16MDFOwG0> M{HkOYlvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk> Mlu3NlUyODl|NkC=
CaOV3 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{L1eVczKGh? MlHsTWM2OD16Nj6xJO69VQ>? NHm0RWYzPTB4OEi0PS=>
OVCAR-3 NWS2dJFsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\WNXg4OiCq NH\DVFBKSzVyPUG3PU42KM7:TR?= Mn\WNlUxPjh6NEm=
OVCAR-5 NG\RUoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYG3NkBp NIHicFNKSzVyPUe1Mlch|ryP MmiwNlUxPjh6NEm=
SKOV-3 M4T3cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV:3NkBp NWjINpA{UUN3ME21NFQh|ryP MkXkNlUxPjh6NEm=
OVCAR-4 M{jxdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrRVW84OiCq MYrJR|UxRTJ7MD62JO69VQ>? MX:yOVA3QDh2OR?=
OVCAR-8 NIXWdpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1r1WVczKGh? NUDwcXJNUUN3ME22PVAvOiEQvF2= NYGw[HpiOjVyNki4OFk>
MA148 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzqNlQhcA>? NUHndlc3UUN3ME24N{436oDLwsJihKkyNjRizsznM41t NVnoSmRWOjR6M{GwPVE>
A549 NF60XnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUTCfYFKOjRiaB?= MUnJR|UxRTd5Nj6w5qCKyrIkgJmxMlkh|rypL33s M2HmSlI1QDNzMEmx
MDA-MB-231 M1G4b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXZNlQhcA>? MkfGTWM2OD15NEiuNQKBkcLz4pEJNU4yKM7:Zz;tcC=> NH;ObJIzPDh|MUC5NS=>
NCI-ADR/RES  MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\3eG8xOjRiaB?= MkPETWM2OD1zN{WzMlDjiIoEsfMAjVQvPCEQvHevcYw> M{fzOFI1QDNzMEmx
MA148 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4LB[FQ5KGh? MWPJR|UxRTJ6LkJihKnDueLCiUGuNEDPxGdxbXy= NUHncGZ{OjR6M{GwPVE>
A549 NVr1NnE3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYmxW5FyPDhiaB?= M1y1VWlEPTB;MUG4MlDjiIoEsfMAjVEvOiEQvHevcYw> M4LwV|I1QDNzMEmx
MDA-MB-231 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUm0PEBp MVHJR|UxRTF6Mz6w5qCKyrIkgJmxMlIhKM7:Zz;tcC=> MW[yOFg{OTB7MR?=
NCI-ADR/RES  NGTZXG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWq0PEBp M1PC[WlEPTB;MUmzMlDjiIoEsfMAjVEvQSEQvHevcYw> M1ru[lI1QDNzMEmx
MA148 M3nHWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWjWNnhnPzJiaB?= MnXOTWM2OD1zMz635qCKyrIkgJmxMlIh|rypL33s M4i1bVI1QDNzMEmx
A549 NWnNb2l1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHT5RlY4OiCq MoL1TWM2OD14ND6z5qCKyrIkgJmxMlEh|rypL33s M4XXWFI1QDNzMEmx
MDA-MB-231 NHjLNXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXEToVKPzJiaB?= NXP5[VhZUUN3ME25PU426oDLwsJihKkyNjFizsznM41t MUOyOFg{OTB7MR?=
NCI-ADR/RES  NU\F[41OT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13xTlczKGh? MYfJR|UxRTN5LkVihKnDueLCiUGuO{DPxGdxbXy= M4KzSlI1QDNzMEmx
A549 NYHmXWlxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULhfFB7PzJiaB?= NEHvWm9FVVOR NFHxd5dKSzVyPUG1Nk41ODlizszN NFzPUoczPDd{MUOyNy=>
NCI-H157 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkLaO|IhcA>? MYnEUXNQ NEfRW2lKSzVyPUi5Mlk4PyEQvF2= M{\vR|I1PzJzM{Kz
PC9 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjFO|IhcA>? MXPHR|UxRTdzLkdCtVkvPSEEtV2= M13IOlI1PjF6OEC5
A549  MnjkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW[3NkBp Ml;ES2M2OD1zM{dCtVMyNjZiwsXNxsA> M1LIS|I1PjF6OEC5
PC9 MXTBdI9xfG:|aYOgRZN{[Xl? M4O5WVExOCEEtV2= NHXneJk4OiCq NELycYVqdmS3Y3XzJIFxd3C2b4Ppdy=> MmLWNlQ3OTh6MEm=
A549  MUXBdI9xfG:|aYOgRZN{[Xl? MkD0NVAxKML3TR?= MXW3NkBp MmS4bY5lfWOnczDhdI9xfG:|aYO= MmraNlQ3OTh6MEm=
A549 M2P5dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHxOnAzPCCq NF;1NHZKSzFyPUGuOFc3KG6P NVfnWo1mOjR|OU[0N|c>
H1299 M33ze2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjXNlQhcA>? M1uxTGlEOTB;MD60OFMhdk1? MkGyNlQ{QTZ2M{e=
HCC15 NYjuXZI{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHG3VW8zPCCq M3q0dWlEOTB;MD6zOFYhdk1? NVHEVJBtOjR|OU[0N|c>
H157 NXL1cYNiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;WSIdEOjRiaB?= NYH6O2VXUUNzME2wMlgyKG6P NGO5SJAzPDN7NkSzOy=>
A2780 NWrXZ3c{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTF2LkFihKnDueLCiUGuOEDPxE1? M{nReFI1OjB7Nkmz
A2780cisR NWHuV3FvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3xWoFKSzVyPUS4MlnjiIoEsfMAjVMvQSEQvF2= NHnSfFIzPDJyOU[5Ny=>
A2780ZD0473R M1TW[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTZ2LkdihKnDueLCiUOuNkDPxE1? NIXodnUzPDJyOU[5Ny=>
SKOV-3 Mnr5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDkTWM2OD12Mz605qCKyrIkgJmzMlkh|ryP M1;qd|I1OjB7Nkmz

... Click to View More Cell Line Experimental Data

In vivo In A2780 tumor xenografts, Carboplatin (60 mg/kg via i.p.) given as single agents shows a modest antitumor effect with the relative tumor volumes on day 6 of 8.4 compared to the control of 11.9, and the day 6 tumor weights relative to control (T/C) of 67%. [1] For the VC8 (Brca2-deficient) xenografts, Carboplatin treatment delays tumor growth and reduces tumor mass by 42% compared to the vehicle group. [3]

Protocol

Cell Research:

[1]

+ Expand
  • Cell lines: A2780, SKOV3, IGROV-1 and HX62
  • Concentrations: 0-200 μM
  • Incubation Time: 72 hours
  • Method:

    3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide (MTT) assays: Exponentially growing A2780, SKOV3, IGROV-1 and HX62 ovarian cancer cells are plated in 96 well plates. A range of drug concentrations are added and the plates are incubated for 72 hours to allow for 3–4 doubling times. Each experiment is carried out in triplicate. Sulforhodamine B (SRB) assays: Exponentially growing A2780 cells are plated in 96 well microtitre plates. For experiments studying concomitant exposure, cells are exposed to increasing concentrations of both drugs for 96 hours. For experiments studying the effect of sequence of exposure to 17-AAG or carboplatin cells are exposed to increasing concentrations of 17-AAG or carboplatin for 24 hours. A period of 24-hour exposure to the first agent is chosen so that the A2780 cells would be exposed to the first drug for at least one doubling time (18-24 hours). The cells are then washed with sterile phosphate buffered saline and the medium is replenished. Following this, the second drug (to which the cells are not exposed to in the first 24 hours) or medium is added for 96 hours. All experiments are carried out in triplicate. The results of combination studies are analyzed using the well-established principles of median effect analysis method. The effects of the combination are calculated using an in-house spreadsheet.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: The A2780 human ovarian cancer cell line is grown as a subcutaneous xenograft in female athymic NCr nude mice (nu/nu) in each flank.
  • Formulation: Carboplatin is dissolved in 43% ethanol, 33% polypropylene glycol and 24% cremaphor diluted 1:7 with sterile water.
  • Dosages: ≤60 mg/kg
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro Water 14 mg/mL warmed (37.71 mM)
DMSO Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
water
For best results, use promptly after mixing.
14mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 371.25
Formula

C6H12N2O4Pt

CAS No. 41575-94-4
Storage powder
in solvent
Synonyms JM-8, CBDCA, NSC 241240

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03126916 Recruiting Childhood Ganglioneuroblastoma|Childhood Neuroblastoma|INRG Stage L2|INRG Stage M|INRG Stage MS|NMYC Gene Amplification|Recurrent Neuroblastoma Children''s Oncology Group|National Cancer Institute (NCI) May 9 2018 Phase 3
NCT03519971 Recruiting Non-Small Cell Lung Cancer AstraZeneca April 9 2018 Phase 3
NCT03095352 Recruiting Breast Cancer|Chest Wall Disease University of California San Francisco|Mayo Clinic|Johns Hopkins University|Translational Breast Cancer Research Consortium|Massachusetts General Hospital September 9 2017 Phase 2
NCT03432598 Recruiting Locally Advanced or Metastatic Lung Cancer BeiGene August 9 2017 Phase 2
NCT02775435 Recruiting Non-small Cell Lung Cancer Merck Sharp & Dohme Corp. June 9 2016 Phase 3
NCT02151149 Completed Non-Small Cell Lung Cancer|Carcinoma|Squamous Cell Carcinoma|Adenocarcinoma|Carcinoma Large Cell|Lung Neoplasm Celgene June 9 2014 Phase 4

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Can you advise what solvent to use and the concentration for S1215 for in vitro use?

  • Answer:

    DMSO will affact the activity of platinum agents. For in vitro use, according to our experience in dissolving this compound, we didn't find any solvent can dissolve it alone, but S1215 can be dissolved in co-solvent ethanol:water=1:2 at 15 mg/ml. We didn't test the stablility of the drug in such vehicle, so it is recommended to prepare the solution just before use.

DNA/RNA Synthesis Signaling Pathway Map

Related DNA/RNA Synthesis Products

Tags: buy Carboplatin | Carboplatin supplier | purchase Carboplatin | Carboplatin cost | Carboplatin manufacturer | order Carboplatin | Carboplatin distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID